Tag: DENV-2

1. In part 1, phase 3 of this randomized controlled trial, the overall vaccine efficacy of TAK-003 (dengue vaccine candidate) was approximately 80% among children ages 4 to 16 years old. 2. In addition, the vaccine increased the number of participants with seropositivity against dengue and showed to have significant...